This course was last updated on
December 31, 2018
CME credit has expired.


This text-based CME activity reviews the recent clinical developments in the immunotherapy and immunomodulatory therapeutic modalities for high-risk non-muscle-invasive bladder cancer as well as for locally advanced or metastatic disease. Learn more about the current and emerging standards of care as well as safety and efficacy data from the select clinical trials in patients with bladder cancer.

Content Areas

  • Intravesical BCG
  • Immune checkpoint blockade
  • rAd–IFNα/Syn3
  • CG0070
  • Vicinium
  • irRECIST
  • irAEs

Target Audience

The target learning audience is oncologists, urologists and other healthcare providers who care for patients with bladder cancer.

This activity is supported by an independent educational grant from Ferring Pharmaceuticals, Inc.


Neal D. Shore, MD
Neal D. Shore, MD
Director, CPI
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Enter your information to begin.
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
Opens: December 31, 2018
Expires: December 30, 2019
Target Audience: Oncologists
Other Healthcare Providers